Traws Pharma, Inc. TRAW PHARMA

Healthcare · Biotechnology · United States

https://www.trawspharma.com

Company Profile ↓

$0.55

-66.31% 1Y

Mkt Cap$8.45M

P/E-0.30

P/B4.41

52W High$3.13

52W Low$0.44

Book Value$0.11

EPS (TTM)$-1.83

Company Overview

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Recent Developments

Dec 2025 Revenue of $2.79M (+1134.5% YoY); net profit $9.17M.
Trailing 12 Months Year-on-year growth — revenue +1134.5%.
5-Year Trend Long-term compounding — revenue CAGR 5.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	4.96%
1 Year:	1,134.51%

Stock Price Performance

1 Year:	-66.31%
6 Months:	-66.92%
3 Months:	-59.67%
1 Month:	+4.25%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$0.44 $3.13

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)44.55 · Neutral

Price Performance

1M+4.25%

3M-59.67%

6M-66.92%

1Y-66.31%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 82.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.30

Industry PE

24.83

Forward P/E

-0.29

PEG Ratio

Book Value

$0.11

Price to Book

4.41

P/S

inf

EV/EBITDA

-0.12

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

4.96%

Profit 5Y

Revenue (YoY)

1,134.51%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-99.40%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.53

EPS (TTM)

$-1.83

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.87

Current Ratio

0.93

Debt

Total Assets

$8.16M

Current Assets

$5.67M

Working Capital

$-3.17M

Ownership

Promoter Holding

5.33%

Chg in Prom Hold

-0.05%

FII / Inst Holding

40.06%

Chg in FII Hold

-9.49%

Financial Snapshot

Enterprise Value

$8.45M

Total Revenue (TTM)

EBITDA

$-21.40M

Free Cash Flow

$-13.33M

Operating Cash Flow

$-16.85M

Shares Outstanding

15.37M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TRAW Traws Pharma, Inc. PHARMA	0.55	-0.30	$8.45M	0.00%	-	-	4.96%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57.00K	-	-	57.00K	-	57.00K	2.73M	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.26M	3.98M	4.05M	7.37M	6.95M
Operating Income	-18.73M	-16.76M	-14.89M	-13.36M	-12.35M	-8.96M	-5.88M	-7.52M	-5.40M	-4.32M	-6.79M	-6.07M	-6.76M	-5.90M	-5.64M	-5.59M	-7.24M	-3.63M	-5.10M	-5.12M	-7.34M	-6.27M	-4.10M	-4.64M	-3.99M	-4.13M	-4.12M	-5.64M	-6.14M	-4.61M	-5.09M	-5.21M	-123.35M	-8.54M	-	-5.20M	-1.25M	-4.05M	-7.37M	-6.95M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.20M	-1.25M	-4.04M	-7.32M	-6.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.49M	-915.00K	-3.96M	-7.44M	-7.11M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-18.68M	-16.75M	-14.88M	-	-12.34M	-8.96M	-5.87M	-7.24M	-5.38M	-1.60M	-8.34M	-2.58M	-6.96M	-5.09M	-4.48M	-5.35M	-7.60M	-3.56M	-4.59M	-	-	-	-	-	-	-	-	-	-	-4.25M	-4.74M	-4.98M	-123.14M	-8.47M	-	21.49M	-915.00K	-3.96M	-7.44M	-7.11M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.32	-0.27	-0.22	-0.20	-0.19	-0.26	-0.28	-0.20	-5.64	-5.92	-20.52	-1.49	-	2.09	-0.11	-0.34	-	-0.53
R&D Expense	14.25M	12.90M	11.89M	10.39M	9.50M	6.51M	5.28M	5.82M	5.56M	3.99M	4.89M	4.61M	5.14M	4.58M	4.07M	3.98M	4.08M	3.90M	3.52M	3.37M	4.80M	4.19M	1.94M	1.85M	1.76M	2.00M	2.04M	3.59M	4.08M	2.46M	2.46M	1.91M	-	-	-	2.51M	-	-	-	4.91M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.49M	46.19M	4.75M	800.00K	11.46M	5.55M	787.00K	1.23M	2.18M	231.00K	-	226.00K	226.00K	226.00K	2.79M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	19.85M	20.52M	25.14M	20.66M
Operating Income	-27.57M	-22.28M	-62.22M	-63.74M	-23.97M	-23.70M	-25.74M	-23.28M	-21.70M	-24.99M	-	-19.63M	-20.30M	-24.91M	-17.88M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-19.61M	-20.28M	-24.90M	-17.81M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-18.96M	-18.95M	-166.52M	9.17M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net Income	-26.29M	-29.91M	-62.54M	-63.68M	-23.98M	-19.67M	-24.09M	-20.57M	-21.50M	-25.16M	-	-18.96M	-18.95M	-166.52M	9.17M
Diluted EPS	-	-	-	-	-	-	-	-	-	-2.17	-	-22.75	-22.57	-35.21	0.82
R&D Expense	22.62M	52.76M	50.18M	49.42M	25.89M	20.07M	19.12M	16.92M	15.54M	16.90M	7.30M	11.41M	11.43M	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	83.85M	105.15M	47.34M	23.45M	23.23M	4.98M	17.92M	23.67M	19.99M	-	39.37M	22.68M	24.96M	10.62M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	39.35M	22.66M	24.95M	7.98M
Cash & Equivalents	7.34M	2.71M	81.53M	60.01M	43.58M	19.80M	21.40M	-	-	-	-	-	38.76M	20.82M	21.34M	3.82M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	29.00K	18.00K	1.76M	3.79M
Total Liabilities	-	-	40.84M	24.25M	23.71M	12.61M	18.11M	15.84M	12.54M	12.10M	13.81M	-	11.06M	12.01M	56.59M	11.25M
Current Liabilities	-	-	25.38M	10.34M	10.26M	7.61M	10.16M	9.98M	8.44M	8.29M	10.02M	-	8.05M	9.22M	11.53M	11.15M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Equity	-108.72M	-138.42M	-158.31M	80.41M	22.75M	10.01M	4.30M	-11.69M	5.39M	11.57M	6.17M	-	28.31M	10.67M	-31.63M	-629.00K
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	837.04K	840.14K	3.65M	9.07M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-15.81M	-23.82M	-22.70M	-20.83M	-23.07M	-	-16.29M	-17.93M	-29.79M	-18.18M
Investing Cash Flow	-	-	-	-	-	-	-	-55.00K	-15.00K	-	0	-14.00K	-3.65M	-2.58M
Financing Cash Flow	-	-	-	-	17.42M	6.36M	35.66M	26.65M	19.36M	-	0	0	33.98M	3.20M
Capital Expenditure	-256.00K	-279.00K	-609.00K	-228.00K	-	-	-	-55.00K	-15.00K	-	-	-14.00K	-	-2.58M
Free Cash Flow	-	-	-	-	-	-	-	-20.89M	-23.09M	-	-16.29M	-17.95M	-29.79M	-20.77M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-16.29M	-17.95M	536.00K	-17.57M

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-1,854.3%	-48.2%	-1,309.1%	-7,968.0%	-209.3%	-427.4%	-3,270.3%	-1,895.9%	-994.0%	-10,819.5%	-	-8,684.5%	-8,981.4%	-11,022.1%	-640.7%
Net Margin %	-1,768.3%	-64.8%	-1,315.9%	-7,960.3%	-209.3%	-354.6%	-3,061.2%	-1,675.3%	-985.0%	-10,890.5%	-	-8,391.2%	-8,384.1%	-73,682.7%	328.7%
ROE %	19.0%	18.9%	-77.8%	-279.9%	-239.6%	-457.7%	206.1%	-381.9%	-185.8%	-407.4%	-	-67.0%	-177.5%	526.5%	-1,457.9%
ROCE %	-	-38.1%	-65.6%	-171.9%	-151.3%	-181.3%	515.0%	-245.5%	-141.1%	-250.8%	-	-62.7%	-150.8%	-185.5%	3,379.0%

Shareholding Pattern

Insiders

5.33%

Institutions

40.06%

Public Float

42.31%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Orbimed Advisors LLC.	7.83%	1.20M	$589.60K
2	Ally Bridge Group (NY) LLC	5.12%	786.24K	$385.25K
3	Adage Capital Partners GP L.L.C.	4.75%	730.00K	$357.70K
4	Adar1 Capital Management, LLC	3.89%	597.73K	$292.89K
5	Lynx1 Capital Management Lp	3.64%	559.47K	$274.14K
6	Ikarian Capital, LLC	3.11%	478.14K	$234.29K
7	Sphera Funds Management Ltd.	2.59%	398.49K	$195.26K
8	Vanguard Capital Management LLC	2.15%	330.05K	$161.72K
9	Jane Street Group, LLC	1.41%	216.01K	$105.84K
10	Alyeska Investment Group, L.p.	1.07%	164.38K	$80.54K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TRAW

Google News Fri, 12 Jun 2026

Why Did TRAW Stock Slump 28% After Hours? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNbjRxeURkZl9wN2JWV19SRW1KMmNFc19aR0NwaEFLMHFSM19IaGNNQmcwY0NuQzBISXlaLXRhNlZWck1wejNMQWRQVU9IVmtkTENlZ0VUb0x6QkRBSDBIXzN1TkF5WjFsZzBaZmJsNWJ3bE1rcXZORmdaSF9MejB4TzRwaXdFV1dzZk04TT…

Google News Sun, 10 May 2026

TRAW Stock Price and Chart — NASDAQ:TRAW - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE81NXdVSkRpeTdhd0pkZkZxa2xQa2MxN1JBMWN2X1I2a0xGa0xjbHZCajdDdXRVbUx3MHcwbVVBTmFyR2w5SjlOUFA5Mk8zbnphVnFLT3RqNFkxRGNf?oc=5" target="_blank">TRAW Stock Price and Chart — NASDAQ:TRAW</a…

Google News ue, 14 Jul 2026

Stock option grant to Traw Pharma (TRAW) director John Leaman - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQQjRiZjlXTXlNNFh0Vk50bzdnVXZXcUptUktNV1BJVXJrZm94LU0zMWxVVVpnVDg0MG16WGk1dk5UeE5nc0xaamZySVlkQnVwSGhHakRkcjhnaWljSk1RY2taTDFtMzgxQVk3OW9iVzlIOEJFaUVjemg5Sm5nYnM3SmJqcGZKd0N5eUNJdU…

Google News Wed, 29 Apr 2026

Traws Pharma Stock (TRAW) Opinions on Insider Purchase - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPOW1UbXc4N2s2YTlmUXUzckNxRjhkbnpCWXVhWkIyanFGYXFNYlNjWkQ4V0dZZi1fMmI3TUpKTjlnQTY2b0FOYTNEbm9FXzJ6YUN1SnhXdVhHUEhGVTJmMEkxUjdUVS01VE5lU0hvTTNSWWRVRWpQSnBRcFR6Vnd4VTdObERSekotanZDTG…

Google News Fri, 08 May 2026

TRAW Stock Pops On Volatile Run As Traders Eye Breakout - timothysykes.com

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9mYlloeTN0MERtVlVmWS14WnhTd1ItckNQdk8ybGVBMkpvN2RYVnNQM2w1VlB3SjBmMW4wQ1NyUUV5WkYyVlUtcVVTdWFGQnljSzV3VFk4NmdmOEVIVzJyOFhpYldiRnlTbUhPeE1yQ1IzVDNlNUdJ?oc=5" target="_blank">TRAW St…

Google News Wed, 27 May 2026

TRAW - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5mY2xsbldLd05OUmVUM05GMkVPSWZOSEl1cFY4eGx5Tl9hSldJbzJfVDVzTXNOSEk3TkRVZEtBOTRNdEhnaWc?oc=5" target="_blank">TRAW</a>  <font color="#6f6f6f">Finviz</font>…

TRAW — Frequently Asked Questions

What is the current share price of Traws Pharma, Inc. (TRAW)?

As of 2026-09-19 21:16 PDT, Traws Pharma, Inc. (TRAW) trades at $0.55 on NasdaqCM. Its 52-week range is $0.44 to $3.13.

What is the market capitalisation of TRAW?

Traws Pharma, Inc. (TRAW) has a market capitalisation of $8.45M on NasdaqCM.

What is the P/E ratio of TRAW?

TRAW trades at a trailing price-to-earnings (P/E) ratio of -0.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.41.

Is TRAW a good stock to buy?

This page provides a data-driven analysis of Traws Pharma, Inc. (TRAW), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Traws Pharma, Inc. TRAW PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Why Did TRAW Stock Slump 28% After Hours? - finance.yahoo.com

TRAW Stock Price and Chart — NASDAQ:TRAW - tradingview.com

Stock option grant to Traw Pharma (TRAW) director John Leaman - Stock Titan

Traws Pharma Stock (TRAW) Opinions on Insider Purchase - Quiver Quantitative

TRAW Stock Pops On Volatile Run As Traders Eye Breakout - timothysykes.com

TRAW - Finviz

TRAW — Frequently Asked Questions

What is the current share price of Traws Pharma, Inc. (TRAW)?

What is the market capitalisation of TRAW?

What is the P/E ratio of TRAW?

Is TRAW a good stock to buy?

Explore More